Latest Content

Unmet need is likely a new battlefield impacting prior authorization.

Artisan Partners' David Samra is publicly calling for Novartis to overhaul its board and compensation structure following back-to-back trial failures.

Dr. Elena Christofides on why the overnight dexamethasone suppression test is the only cortisol screen that actually identifies HPA dysfunction.

Kura Oncology spins out Caspian Therapeutics to apply its menin inhibitor expertise to diabetes — with Eli Lilly validating the science.

Model N's Jesse Mendelsohn examines the growing stakes surrounding the 340B Drug Pricing Program — and how claims data, rebate models and simmering legal challenges are influencing manufacturer response and strategy today.

HHS confirms permanent directors for CDER and CBER and creates FDA's first-ever Deputy Commissioner for Technology and AI.

Dr. Elena Christofides on why cortisol dysregulation may explain why so many patients fail to respond to GLP-1 and incretin therapies.

Back Bay’s director discusses why IBD remains underserved — JAK inhibitor constraints, emerging oral mechanisms, and the durability gap.

Aptar Pharma and Aceso Therapeutics team up to advance an inhaled cystic fibrosis therapy, Moonwalk Biosciences raises a $70 million Series B for its fat-targeted obesity platform, and Sebastian Arana of MilliporeSigma talks through the real cost of manufacturing flexibility.

Moonwalk Biosciences has closed a $70 million Series B to advance its adipose-targeted RNAi platform toward first-in-human studies.

Sebastian Arana, head of process solutions at MilliporeSigma, discusses the operational tradeoffs facilities face as they move toward multi-modality production and the persistent cost and scale-up challenges shaping cell and gene therapy, mRNA, and ADC manufacturing.

Back Bay’s director discusses why IBD remains underserved — JAK inhibitor constraints, emerging oral mechanisms, and the durability gap.

Christian Thienel on the oral IBD mechanisms generating the most excitement — SIK2, oral IL-23, TYK2 — and why multiple could succeed.